Alpha Teknova (TKNO) Non-Current Deffered Revenue (2020 - 2021)
Alpha Teknova's (TKNO) quarterly Non-Current Deffered Revenue came in at $269000.0 in Q4 2021, up 31.86% year-on-year from $204000.0 in Q4 2020, and up 1.89% on a QoQ basis from $264000.0 in Q3 2021.
Alpha Teknova (TKNO) Non-Current Deffered Revenue (2020 - 2021) Analysis & Trends
Alpha Teknova (TKNO) has 2 years of Non-Current Deffered Revenue data on file, last reported at $269000.0 in Q4 2021.
- On a quarterly basis, Non-Current Deffered Revenue rose 31.86% year-over-year to $269000.0 in Q4 2021; TTM through Dec 2021 was $269000.0, a 31.86% increase from a year earlier, with the FY2021 full-year figure at $269000.0, up 31.86% from the prior year.
- Non-Current Deffered Revenue for Q4 2021 stood at $269000.0, up from $264000.0 in the prior quarter.
- Over the last five years, Non-Current Deffered Revenue for TKNO reached as high as $269000.0 in Q4 2021 and fell as low as $204000.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Alpha Teknova | 278.75 Mn | 260.97 Mn | 3.78 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 269,000.00 |
| Sep 30, 2021 | 264,000.00 |
| Jun 30, 2021 | 253,000.00 |
| Dec 31, 2020 | 204,000.00 |